MelissaHe Ph.D.

Associate

San Diego + 1.858.314.1154

Connect:

Share

Dr. Melissa He prosecutes patents and manages patent portfolios worldwide in the areas of pharmaceuticals, biotechnology, and chemistry. Her practice encompasses global patent portfolio development and management, due diligence investigation, patentability and validity assessments, freedom-to-operate analysis, and patent strategy counseling.

Melissa is experienced in the areas of immunotherapies (e.g., monospecific and multispecific antibodies), gene therapies (e.g., mRNA-based, viral or nonviral vector-based therapeutics), cell therapies (e.g., CAR-T and CAR-NK therapeutics), lipid nanoparticles, biomarkers and diagnostics, and small-molecule pharmaceuticals. Exemplary small molecule pharmaceuticals that Melissa has been involved with include REVLIMID®, iberdomide, and mezigdomide.

Her representative clients include AbbVie, Merck, and BMS/Celgene, as well as other start-up companies, established companies, academic institutions, and investment firms.

Melissa also has experience in patent litigation and post-grant proceedings, including inter partes review (IPR) before the Patent Trial and Appeal Board (PTAB).

Prior to joining Jones Day, Melissa worked in a patent litigation team at an international law firm for more than three years and worked as a scientist for more than 10 years. Melissa is a co-inventor of patent applications and the first author of scientific publications in journals including Science Translational Medicine and Journal of Medicinal Chemistry. Her publications have been featured in "Research Highlights" in Nature Reviews Drug Discovery and selected for American Chemical Society Editors' Choice.

Experience

  • Bambusa Therapeutics develops global patent portfolios for bispecific antibodies to treat immunological and inflammatory disordersJones Day represents Bambusa Therapeutics, Inc. in developing global patent portfolios related to various bispecific antibodies for the treatment of immunological and inflammatory (I&I) disorders.
  • METiS Pharmaceuticals develops global patent portfolios related to lipid nanoparticles for mRNA-based gene therapiesJones Day is representing METiS Pharmaceuticals, Inc. in connection with the establishment of global patent portfolios related to lipid nanoparticles (LNP) and uses thereof in various mRNA-based gene therapies.
  • Exegenesis Bio establishes global patent portfolio related to AAV-based gene therapiesJones Day is representing Exegenesis Bio in connection with the establishment of global patent portfolios related to AAV-based gene therapies for treating central nervous system (CNS), ocular and liver related diseases.
  • AbbVie develops patent portfolio related to adalimumab formulationsJones Day is representing AbbVie Inc. in connection with the development of global patent portfolios related to formulations for AbbVie's antibody adalimumab, marketed as HUMIRA®.
  • Celgene acquired by Bristol-Myers Squibb for approximately $74 billionJones Day advised Celgene Corporation (NASDAQ: CELG) in connection with the intellectual property and technology transactions aspects of its cash-and-stock merger with Bristol-Myers Squibb (NYSE: BMY) which has an equity value of approximately $74 billion.
    • View All

    Additional Speaking Engagements

    • January 18, 2024
      Foreign Filing Licenses and Other Issues Related to Cross-pacific Patent Inventions

    Before sending, please note:

    Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.